Hye Y Kim1, So Y Park1, Mi H Lee1, Jee H Rho1, Yoo J Oh1, Hye U Jung1, Seung H Yoo1, Na Y Jeong1, Hye J Lee1, SungHwan Suh2, Su Y Seo3, JaeHun Cheong4, Jin S Jeong5, Young H Yoo6. 1. Dong-A University College of Medicine and Mitochondria Hub Regulation Center, Busan 602-714, South Korea. 2. Department of Endocrinology, Dong-A University College of Medicine, Busan 602-714, South Korea. 3. Department of Microbiology, Dong-A University College of Medicine, Busan 602-714, South Korea. 4. Department of Molecular Biology, College of Natural Sciences, Pusan National University, Busan 609-735, South Korea. 5. Department of Pathology, Dong-A University College of Medicine, Busan 602-714, South Korea. 6. Dong-A University College of Medicine and Mitochondria Hub Regulation Center, Busan 602-714, South Korea. Electronic address: yhyoo@dau.ac.kr.
Abstract
BACKGROUND & AIMS: Most studies on the role of STAMP2 in metabolism have used adipose tissue. Little knowledge exists concerning the role of STAMP2 in the liver, which is a metabolically central target. We hypothesized that STAMP2 is involved in non-alcoholic fatty liver disease (NAFLD) pathogenesis. METHODS: We examined our hypothesis using human NAFLD patient pathology samples and a high-fat diet (HFD)-induced NAFLD mouse model. The molecular mechanism underlying hepatic STAMP2-mediated lipid imbalance was explored using an oleic acid (OA)-induced NAFLD in vitro model. RESULTS: Noticeably, the expression level of STAMP2 protein was reduced in the livers obtained from NAFLD patients and HFD-induced NAFLD mice. In vivo knockdown of hepatic STAMP2 by siRNA accelerated hepatic steatosis and insulin resistance in mice fed a HFD. Conversely, the delivery of adenoviral STAMP2 (Ad-STAMP2) improved hepatic steatosis in HFD-induced NAFLD mice. The expression of lipogenic or adipogenic factors was increased in both in vitro and in vivo NAFLD models but was reversed by Ad-STAMP2. Adenoviral overexpression of STAMP2 improved insulin resistance in the HFD-induced NAFLD mice. In vivo and in vitro assays demonstrated that STAMP2 modulates insulin sensitivity and glucose metabolism and that STAMP2 counteracts OA-induced insulin resistance by modulating insulin receptor substrate-1 stability. CONCLUSIONS: The present study revealed that hepatic STAMP2 plays a pivotal role in preventing HFD-induced NAFLD and that STAMP2 overexpression improves hepatic steatosis and insulin resistance in NAFLD. Our findings indicate that STAMP2 may represent a suitable target for interventions targeting NAFLD.
BACKGROUND & AIMS: Most studies on the role of STAMP2 in metabolism have used adipose tissue. Little knowledge exists concerning the role of STAMP2 in the liver, which is a metabolically central target. We hypothesized that STAMP2 is involved in non-alcoholic fatty liver disease (NAFLD) pathogenesis. METHODS: We examined our hypothesis using human NAFLD patient pathology samples and a high-fat diet (HFD)-induced NAFLD mouse model. The molecular mechanism underlying hepatic STAMP2-mediated lipid imbalance was explored using an oleic acid (OA)-induced NAFLD in vitro model. RESULTS: Noticeably, the expression level of STAMP2 protein was reduced in the livers obtained from NAFLD patients and HFD-induced NAFLD mice. In vivo knockdown of hepatic STAMP2 by siRNA accelerated hepatic steatosis and insulin resistance in mice fed a HFD. Conversely, the delivery of adenoviral STAMP2 (Ad-STAMP2) improved hepatic steatosis in HFD-induced NAFLD mice. The expression of lipogenic or adipogenic factors was increased in both in vitro and in vivo NAFLD models but was reversed by Ad-STAMP2. Adenoviral overexpression of STAMP2 improved insulin resistance in the HFD-induced NAFLD mice. In vivo and in vitro assays demonstrated that STAMP2 modulates insulin sensitivity and glucose metabolism and that STAMP2 counteracts OA-induced insulin resistance by modulating insulin receptor substrate-1 stability. CONCLUSIONS: The present study revealed that hepatic STAMP2 plays a pivotal role in preventing HFD-induced NAFLD and that STAMP2 overexpression improves hepatic steatosis and insulin resistance in NAFLD. Our findings indicate that STAMP2 may represent a suitable target for interventions targeting NAFLD.
Authors: Hannah M Gordon; Neil Majithia; Patrick E MacDonald; Jocelyn E Manning Fox; Poonam R Sharma; Frances L Byrne; Kyle L Hoehn; Carmella Evans-Molina; Linda Langman; Kenneth L Brayman; Craig S Nunemaker Journal: Endocrine Date: 2017-04-12 Impact factor: 3.633
Authors: Xiang Xue; Bryce X Bredell; Erik R Anderson; Angelical Martin; Christopher Mays; Hiroko Nagao-Kitamoto; Sha Huang; Balázs Győrffy; Joel K Greenson; Karin Hardiman; Jason R Spence; Nobuhiko Kamada; Yatrik M Shah Journal: Proc Natl Acad Sci U S A Date: 2017-10-23 Impact factor: 12.779
Authors: Sung Won Lee; Jee Hyun Rho; Sang Yeob Lee; Won Tae Chung; Yoo Jin Oh; Jung Ha Kim; Seung Hee Yoo; Woo Young Kwon; Ju Yong Bae; Su Young Seo; Hokeun Sun; Hye Young Kim; Young Hyun Yoo Journal: Bone Res Date: 2018-07-06 Impact factor: 13.567
Authors: Torstein Lindstad; Su Qu; Jørgen Sikkeland; Yang Jin; Alexandr Kristian; Gunhild M Mælandsmo; Philippe Collas; Fahri Saatcioglu Journal: Oncotarget Date: 2016-08-09